An open-labeled, randomized study comparing systemic interferon-α-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis

American Journal of Gastroenterology

Volumn 96, Issue 6, 2001, Pages 1807-1815

  Hilsden, Robert J ^a   Hodgins, David ^b   Czechowsky, Diana ^b   Verhoef, Marja J ^b   Sutherland, Lloyd R ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ENEMA; MESALAZINE; PREDNISOLONE; ROCERON A; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HISTOLOGY; HUMAN; MALE; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; ULCERATIVE COLITIS;

ADULT; AGED; COLITIS, ULCERATIVE; ENEMA; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; PREDNISOLONE; QUALITY OF LIFE;

EID: 0034967275     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02438-8     Document Type: Article

References (42)

1. Course of ulcerative colitis: Analysis of changes in disease activity over years
2. Incidence of inflammatory bowel disease across Europe: Is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)
3. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: Incidence, prevalence, and survival
4. Incidence and prevalence of ulcerative colitis in Copenhagen County from 1962 to 1987
5. Cyclosporin for inflammatory bowel disease: Mechanisms and possible actions
6. Treatment of ulcerative colitis with high doses of oral prednisolone. The rate of remission, the need for surgery, and the effect of prolonging the treatment
7. Post-translational upregulation of the cell surface-associated alpha component of the human type I interferon receptor during differentiation of peripheral blood monocytes: The role in the biological response to type I interferon
8. Effects of interferon-alpha therapy on immune parameters in immune thrombocytopenic purpura
9. Type I interferons (IFN-alfa, and -beta) suppress cytotoxin (tumor necrosis factor-alpha, and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cells
10. Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosis
11. Interferon-alfa induces circulating tumor necrosis factor receptor p55 in humans
12. Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: Inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist
13. Induction of circulating IL-1 receptor antagonist by IFN treatment
14. Interleukin-1 receptor antagonist plasma concentration is specifically increased by alpha-2A-interferon treatment
15. Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes
16. Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans
17. Interferon-alpha upregulates both interleukin-10 and interferon-gamma production by human CD4+ T cells
18. Treatment of Crohn's disease with interferon. A preliminary clinical trial
19. Immunological and clinical effects of interferon-gamma on Crohn's disease
20. The effect of interferon alpha-2a on clinical and endoscopic findings in chronic active ulcerative colitis. Inflammatory bowel diseases: Pathophysiology as basis of treatment
21. Interferon-alfa-2a (Roferon) treatment of inflammatory bowel disease in children and adolescents. Inflammatory bowel diseases and morbus Hirschsprung
22. Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease
23. Alpha-interferon therapy in Crohn's disease: Initial clinical results
24. Induction of remission by interferon-alfa in patients with chronic active ulcerative colitis
25. Interferon treatment in mild to moderate active Crohn's disease: Preliminary results of an open label pilot study
26. Prospective evaluation of interferon alfa in treatment of chronic active Crohn's disease
27. Alpha-interferon was not effective treatment of patients with ulcerative colitis
28. Interferon alpha in the treatment of Crohn's disease and ulcerative colitis. A pilot study
29. The clinical results of interferon treatment in inflammatory bowel disease
30. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis
31. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis
32. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease
33. A new measure of health status for clinical trials in inflammatory bowel disease
34. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion
35. Development and subsequent refinement of the inflammatory bowel disease questionnaire: A quality-of-life instrument for adult patients with inflammatory bowel disease
36. Rectal corticosteroids versus alternative treatments in ulcerative colitis: A meta-analysis
37. Clinical trials
38. Selection factors in clinical trials: Results from the community clinical oncology program physicians patient log
39. Ethical aspects of clinical trials: The attitudes of the public and out-patients
40. Ethical aspects of clinical trials: The attitudes of participants in two non-cancer trials